Nicotinamide Riboside Supplementation in Chronic Kidney Disease (NR-CKD)
Pilot Randomized Crossover Trial of Nicotinamide Riboside in Chronic Kidney Disease (NR-CKD Trial)
This study is testing whether a dietary supplement called nicotinamide riboside, (NR), can be used in adults with moderate chronic kidney disease. NR is a form of vitamin B3 that may help support cellular energy metabolism.
The main goal of this study is to see whether it is feasible for people with chronic kidney disease to take NR daily, complete study visits, and follow the study procedures. The study will also explore whether NR chloride affects markers of mitochondrial health, small blood vessel function, and physical function.
Participants will be randomly assigned to one of two treatment orders. One group will take NR first and placebo second. The other group will take placebo first and NR second. Placebo looks like NR but does not contain active NR. Each treatment period lasts 12 weeks, with an approximately 2-week washout period between treatments. Neither participants nor the study team will know which treatment participants are taking during each period.
Study visits will include blood and urine collection, physical function testing, and noninvasive tests of small blood vessel function. The study will enroll up to 36 adults with moderate chronic kidney disease at the University of California, San Diego.
研究概览
详细说明
Chronic kidney disease is associated with impaired mitochondrial function, vascular dysfunction, reduced physical function, and increased risk of cardiovascular and functional decline. Nicotinamide riboside is a vitamin B3 derivative and NAD+ precursor that may support cellular energy metabolism and vascular health.
This pilot study will evaluate the feasibility of using nicotinamide riboside in adults with moderate chronic kidney disease. The study uses a randomized, double-blind, placebo-controlled crossover design so that each participant receives both nicotinamide riboside chloride and placebo during separate treatment periods.
In addition to feasibility measures, the study will collect exploratory data on mitochondrial, microvascular, and physical function outcomes. These data will help determine whether a larger clinical trial of nicotinamide riboside in chronic kidney disease is practical and scientifically justified.
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习联系方式
- 姓名：Armin Ahmadi, PhD
- 电话号码：619-543-6248
- 邮箱：a3ahmadi@ucsd.edu
研究联系人备份
- 姓名：Rakesh Malhotra, MD, MPH
- 邮箱：r3malhotra@health.ucsd.edu
学习地点
-
-
California
-
San Diego、California、美国、92093
- Altman Clinical and Translation Research Institute
-
接触：
- Armin Ahmadi, PhD
- 电话号码：(619) 543-6248
- 邮箱：a3ahmadi@ucsd.edu
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
Inclusion Criteria:
- Moderate chronic kidney disease not treated with dialysis, defined as eGFR 30-59 mL/min/1.73 m2 using the CKD-EPI equation.
- Urine albumin-to-creatinine ratio (uACR) <300 mg/g.
- Able to provide informed consent.
- Able to walk unassisted from room to room, with usual assistive device allowed if approved by study safety assessment.
- Willing and able to comply with study procedures, visits, and study product administration.
Exclusion Criteria:
- Pregnancy.
- Expectation to start dialysis within 6 months.
- Unable to walk unassisted from room to room.
- Institutionalization or inability to consent.
- End-stage liver disease with cirrhosis.
- HIV.
- Oxygen-dependent COPD.
- Baseline systolic blood pressure >170 mmHg or diastolic blood pressure >100 mmHg.
- Current participation in another interventional trial.
- Use of immunosuppressive medications, including steroids or calcineurin inhibitors.
- Malignancy requiring active treatment or currently under surveillance at the discretion of the investigator.
- Hospitalization for myocardial infarction, unstable angina, cerebrovascular accident, or unstable cardiac chest pain within the prior 3 months.
学习计划
研究是如何设计的？
设计细节
- 主要用途：治疗
- 分配：随机化
- 介入模型：交叉作业
- 屏蔽：三倍
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的：Placebo Then NR
Participants assigned to this arm will receive matched placebo for 12 weeks, followed by an approximately 14-day washout/crossover period, then nicotinamide riboside 1000 mg/day for 12 weeks.
|
Matched placebo will be administered orally for 12 weeks during the placebo treatment period.
The placebo will be identical or substantially similar in appearance to the active nicotinamide riboside study product to maintain blinding.
|
|
实验性的：NR Then Placebo
Participants assigned to this arm will receive nicotinamide riboside 1000 mg/day for 12 weeks, followed by an approximately 14-day washout/crossover period, then matched placebo for 12 weeks.
|
Nicotinamide riboside will be administered orally at a target dose of 1000 mg/day for 12 weeks during the active treatment period.
|
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in plasma cell-free mitochondrial DNA
大体时间：Baseline, Week 12, and Week 26
|
Change in plasma cell-free mitochondrial DNA concentration, measured as mitochondrial DNA copies per mL of plasma using droplet digital PCR.
|
Baseline, Week 12, and Week 26
|
|
Change in urine cell-free mitochondrial DNA
大体时间：Baseline, Week 12, and Week 26
|
Change in urine cell-free mitochondrial DNA concentration, measured using droplet digital PCR and reported as mitochondrial DNA copies normalized to urine osmolarity.
|
Baseline, Week 12, and Week 26
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in skin fingernail capillary density
大体时间：Baseline, Week 12, and Week 26
|
Change in skin capillary density, measured as capillaries per mm2 using capillaroscopy.
|
Baseline, Week 12, and Week 26
|
|
Change in skin blood flow
大体时间：Baseline, Week 12, and Week 26
|
Change in skin blood flow, measured in laser Doppler perfusion units using laser Doppler flowmetry.
|
Baseline, Week 12, and Week 26
|
|
Change in six-minute walk distance
大体时间：Baseline, Week 12, and Week 26
|
Change in distance walked during the six-minute walk test, measured in meters.
|
Baseline, Week 12, and Week 26
|
|
Change in Handgrip Strength
大体时间：Baseline, Week 12, and Week 26
|
Change in handgrip strength, measured in kilograms using handheld dynamometry.
|
Baseline, Week 12, and Week 26
|
|
Change in Timed Up and Go
大体时间：Baseline, Week 12, and Week 26
|
Change in Timed Up and Go test performance, measured in seconds.
|
Baseline, Week 12, and Week 26
|
|
Change in 30-second sit-to-stand
大体时间：Baseline, Week 12, and Week 26
|
Change in the number of chair stands completed during the 30-second sit-to-stand test, measured as repetitions completed in 30 seconds.
|
Baseline, Week 12, and Week 26
|
合作者和调查者
调查人员
- 首席研究员：Armin Ahmadi, PhD、University of California, San Diego
出版物和有用的链接
一般刊物
- Trammell SA, Schmidt MS, Weidemann BJ, Redpath P, Jaksch F, Dellinger RW, Li Z, Abel ED, Migaud ME, Brenner C. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun. 2016 Oct 10;7:12948. doi: 10.1038/ncomms12948.
- Martens CR, Denman BA, Mazzo MR, Armstrong ML, Reisdorph N, McQueen MB, Chonchol M, Seals DR. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018 Mar 29;9(1):1286. doi: 10.1038/s41467-018-03421-7.
- Conze D, Brenner C, Kruger CL. Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults. Sci Rep. 2019 Jul 5;9(1):9772. doi: 10.1038/s41598-019-46120-z.
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- UCSD-NR-001
- 1K01DK147652 (美国 NIH 拨款/合同)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)？
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.